First open-label,single-arm,prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China |
| |
Authors: | Renchi Yang Runhui Wu Jing Sun Feifei Sun Jeremy Rupon Francois Huard Joan M Korth-Bradley Lihong Xu Binyu Luo Yingxue Cathy Liu Pablo Rendo |
| |
Institution: | aInstitute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin;bHematology Oncology Centre, Beijing Children''s Hospital, Capital Medical University, Beijing;cNanfang Hospital, Southern Medical University, Guangzhou;dPfizer (China) Research & Development Co, Ltd, Shanghai, China;ePfizer Inc, Collegeville, PA;fPfizer PIO, Paris, France. |
| |
Abstract: | Background:Nonacog alfa (recombinant factor IX FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement in a real-world setting in China. This study aimed to evaluate the safety and efficacy of nonacog alfa in Chinese patients with hemophilia B.Methods:In this open-label, multicenter study (clinicaltrials.gov identifier {"type":"clinical-trial","attrs":{"text":"NCT02336178","term_id":"NCT02336178"}}NCT02336178), patients received on-demand or prophylactic treatment with intravenous nonacog alfa for approximately 6 months or 50 exposure days, whichever occurred first. The primary safety outcome was medically important events (i.e., development of FIX inhibitors, allergic reactions, and thrombotic events). Key secondary efficacy outcomes included the annualized bleeding rate for on-demand treatment and prophylaxis, response to on-demand treatment, the number of infusions per bleeding event, and the number of breakthrough bleeding events within 48 hours of prophylaxis.Results:Seventy male patients (mean standard deviation] age 7.8 7.2] years) were enrolled (on-demand, n = 37; prophylaxis, n = 57 24 patients were included in both groups]). Thirty-eight (54%) patients had up to 50 FIX exposure days before the study. The only medically important event was a transient low-titer FIX inhibitor (incidence 1.4%, 95% confidence interval, 0–7.7). The mean annualized bleeding rate was 26.3 for on-demand treatment and 6.5 for prophylaxis. A mean (standard deviation) of 1.5 (1.7) nonacog alfa infusions were given per bleeding episode; 78.8% of episodes resolved with 1 infusion. Response was “excellent” or “good” for 88% of the on-demand infusions. Twenty-three bleeding events (n = 11 patients) occurred within 48 hours of 2032 prophylaxis doses (1.13%).Conclusion:In the real-world setting, nonacog alfa is safe and effective for on-demand treatment and for prophylaxis for patients with hemophilia B in China. |
| |
Keywords: | BeneFIX factor IX hemorrhage hypersensitivity prevention safety |
|
|